Gaize, Inc. has announced the launch of their impairment screening solution for cannabis and other drugs. The product is a first-of-its-kind fully automated, non-invasive and portable eye movement test. It’s an objective way to detect the involuntary eye movement changes associated with impairment. Gaize recently completed the world’s largest cannabis impairment clinical trial, which validated the effectiveness of the product.
